Differential restriction patterns of mRNA decay factor AUF1 during picornavirus infections

Permalink
https://escholarship.org/uc/item/4ds4d9g8

Journal
Journal of General Virology, 95(PART 7)

ISSN
0022-1317

Authors
Cathcart, AL
Semler, BL

Publication Date
2014-01-01

DOI
10.1099/vir.0.064501-0

Peer reviewed
Short Communication

Differential restriction patterns of mRNA decay factor AUF1 during picornavirus infections

Andrea L. Cathcart† and Bert L. Semler

Department of Microbiology and Molecular Genetics, School of Medicine, University of California, Irvine, CA 92697, USA

During infection by picornaviruses, the cellular environment is modified to favour virus replication. This includes the modification of specific host proteins, including the recently discovered viral proteinase cleavage of mRNA decay factor AU-rich binding factor 1 (AUF1). This cellular RNA-binding protein was shown previously to act as a restriction factor during poliovirus, rhinovirus and coxsackievirus infection. During infection by these viruses, AUF1 relocates to the cytoplasm and is cleaved by the viral 3C/3CD proteinase. In this study, we demonstrated that replication of encephalomyocarditis virus (EMCV), a picornavirus belonging to the genus Cardiovirus, is AUF1 independent. During EMCV infection, AUF1 relocalized to the cytoplasm; however, unlike what is seen during enterovirus infections, AUF1 was not cleaved to detectable levels, even at late times after infection. This suggests that AUF1 does not act broadly as an inhibitor of picornavirus infections but may instead act as a selective restriction factor targeting members of the genus Enterovirus.

The family Picornaviridae encompasses a wide range of positive-sense RNA viruses that complete their replication cycles in the cytoplasm of infected cells and employ unique mechanisms to alter the cytoplasmic environment to favour virus production. All picornaviruses encode a proteolytically active 3C/3CD protein, which functions in proteolytic processing of the viral polyprotein and in alteration of the cellular environment during infection. Additionally, members of the genus Enterovirus, including poliovirus (PV), coxsackievirus and human rhinovirus (HRV), encode a proteolytically active 2A protein that cleaves specific cellular proteins in infected cells. In contrast, the prototypic member of the genus Cardiovirus, encephalomyocarditis virus (EMCV), encodes a unique 2A protein that is not a proteinase. Despite differences in proteinase-coding capacity, enteroviruses and cardioviruses alter the cellular environment in a similar manner. For example, during the initial stages of infection, modification of host proteins, including the cleavage of eIF4G (for enteroviruses) and dephosphorylation of 4E-BP1 (for EMCV), effectively shuts down cap-dependent translation (Agol & Gmyl, 2010; Castelló et al., 2011; Gingras et al., 1996). Additionally, the cleavage of nucleoporin proteins by the enterovirus 2A proteinase or phosphorylation of nucleoporins by the EMCV leader (L) protein alters the activity of specific nucleocytoplasmic transport pathways (Castelló et al., 2009; Park et al., 2010; Porter & Palmenberg, 2009; Porter et al., 2010; Watters & Palmenberg, 2011). This disruption leads to an increase in cytoplasmic levels of cellular proteins usurped by the virus in its replication cycle, including hnRNP C, SRp20, PTB and La (Back et al., 2002; Fitzgerald & Semler, 2011; Gustin & Sarnow, 2001; Shiroki et al., 1999; reviewed by Castelló et al., 2011).

Restriction factors are important determinants of the outcome of viral infection, and RNA viruses have evolved multiple routes of escape from such limiting factors. To evade the immune response, PV and EMCV degrade the cellular sensors of viral RNA: RIG-I and MDA-5 (Barral et al., 2007, 2009; Papon et al., 2009). Additionally, cleavage of IPS-1 and NF-κB during PV infection and disruption of IRF-3 dimerization by the EMCV L protein act to interrupt IFN signalling (Agol & Gmyl, 2010; Hato et al., 2007; Racaniello, 2010). Recently, the potential disruption of mRNA decay pathways has been discovered for enteroviruses. The decapping enzyme Dcp1a, the exonuclease Xrn1, the deadenylase complex component Pan3 and the mRNA stability factor AU-rich element-binding factor 1 (AUF1) are cleaved or degraded during PV infection (Dougherty et al., 2011; Rozovics et al., 2012), presumably as a viral defence against the degradation of viral RNA during infection.

We recently reported that AUF1, a cellular protein involved in mRNA stability, binds directly to PV stem–loop IV of the 5′ non-coding region (NCR) in vitro and has an inhibitory effect on viral translation and overall viral titres (Cathcart et al., 2013). This AUF1–viral RNA interaction is disrupted by incubation with proteolytically active 3CD, which has been shown to cleave AUF1 in vitro, suggesting...
the cleavage of AUF1 by 3C/3CD may act as a viral defence against AUF1 and the cellular mRNA decay machinery. Additionally, AUF1 relocates to the cytoplasm of PV-infected cells where it partially co-localizes with viral proteins but is excluded from a perinuclear region by peak times of virus replication (Cathcart et al., 2013; Rozovics et al., 2012). The inhibitory effect of AUF1 on viral titre, as well as the relocalization of AUF1 and 3C proteinase cleavage during infection, has been confirmed for other members of the genus Enterovirus, including HRV and coxsackievirus B3 (CVB3) (Cathcart et al., 2013; Rozovics et al., 2012; Spurrell et al., 2005; Wong et al., 2013). In this study, we sought to determine whether AUF1 acts as a broad regulator of picornavirus infections by exploring the potential modification of AUF1 during EMCV infection.

Given the known relocalization of AUF1 to the cytoplasm of enterovirus-infected cells, we first investigated the localization of AUF1 in EMCV-infected cells by confocal microscopy (Fig. 1). HeLa cell monolayers seeded on coverslips were either mock infected (Fig. 1a) or infected with EMCV at an m.o.i. of 20 (Fig. 1b–d) and fixed with formaldehyde at the indicated times post-infection (p.i.). Endogenous AUF1 was visualized using polyclonal anti-AUF1 antibody (Millipore) and Alexa Fluor 488-conjugated goat anti-rabbit IgG (Molecular Probes). In mock-infected cells, AUF1 was predominantly nuclear (Fig. 1a). By 4 h p.i. (Fig. 1c), AUF1 had partially relocalized to the cytoplasm of infected cells, and this relocalization was more dramatic by 6 h p.i. (Fig. 1d). Although EMCV alters nuclear transport via different mechanisms than enteroviruses, AUF1 does relocalize to the cytoplasm during EMCV infection. Notably, the EMCV L protein and PV 2A proteinase are known to modify the same nucleoporins, including Nup153 and Nup62 (Gustin & Sarnow, 2001; Porter & Palmenberg, 2009; Porter et al., 2010).

During enterovirus infections, the electrophoretic mobility of AUF1 is modified, due to the cleavage activity of viral 3C/3CD protease on AUF1 (Rozovics et al., 2012; Wong et al., 2013). To determine whether AUF1 is modified in a similar manner during cardiovirus infection, Western blot analysis was performed on lysates from HeLa cells infected with PV, CVB3, HRV1a or EMCV (Fig. 2). To generate lysates, cell monolayers were mock infected or infected at an m.o.i. of 20 with the indicated virus. Cells were collected at the indicated times p.i., lysed in buffer containing NP-40 and the proteins resolved by SDS-PAGE followed by Western blotting using polyclonal antibody to AUF1. Whilst cleavage of AUF1 was readily seen for cells infected with PV (Fig. 2, lane 2), CVB3 (Fig. 2, lane 4) or HRV1a (Fig. 2, lane 6) by late times after infection, cleavage of AUF1 was not detected in EMCV-infected cells, even at very late times p.i. (Fig. 2, lane 8). Cleavage products of AUF1 were still not detected when twice the amount of total protein was loaded from lysates generated at 6 or 7 h p.i. with EMCV (data not shown). These results demonstrated that AUF1 is differentially modified during infection by picornaviruses. Notably, HRV1a displayed an alternative cleavage pattern of AUF1 when compared with cleavage of AUF1 during CVB3 or PV infection (Fig. 2) (Rozovics et al., 2012). This is consistent with reports of lower stringency in cleavage-site recognition by the HRV 3C proteinase compared with that of PV (Palmenberg, 1990).

To determine the effect of AUF1 on EMCV infection, we used mouse embryonic fibroblast cells genetically deleted for AUF1 (MEF-AUF1<sup>-/-</sup>) (Lee et al., 2008). For the results shown in Fig. 3(a), MEF-AUF1<sup>-/-</sup> (black bars) or MEF-AUF1<sup>+/+</sup> (white bars) monolayers were infected with CVB3, HRV1a or EMCV. As mouse cells lack the PV receptor, PV transcripts corresponding to full-length genomic RNAs were transfected into cells as described by Cathcart et al. (2013). The cells and supernatant were collected at late times p.i., and viral titres were determined by plaque assay on HeLa cell monolayers. As reported previously, PV, CVB3 and HRV1a displayed an increase in viral titre in cells lacking AUF1, demonstrating a negative role for AUF1 in their replication cycle. In contrast, EMCV titres were not significantly different in the presence or absence of AUF1.
absence of AUF1. To confirm this result, a single-cycle growth analysis was performed in HeLa, MEF-AUF1−/− or MEF-AUF1+/+ cell monolayers (Fig. 3b). The titres of EMCV remained similar over the course of infection in both MEF-AUF1−/− and MEF-AUF1+/+ cells (Fig. 3b, 0–8 h p.i.). In contrast to the increase in titre seen in MEF-AUF1−/− cells during enterovirus infection, titres of EMCV were instead slightly lower in MEF cells lacking AUF1 at 10 or 12 h p.i., although not to statistically significant levels (Fig. 3a, b, and data not shown).

Taken together, these results indicate that, although AUF1 relocates to the cytoplasm during EMCV infection, AUF1 is not cleaved to detectable levels in EMCV-infected cells and does not have an effect on overall viral titres. These results suggest a different susceptibility to cellular mRNA decay factors between genera of picornaviruses, despite a similar replication scheme. In accordance with the results reported in this study, translation driven by the EMCV internal ribosome entry site (IRES) has been shown previously to be unaffected by AUF1 in a luciferase reporter assay (Paek et al., 2008). Notably, the secondary structure and IRES trans-acting factor requirements of the EMCV IRES are different than those of enteroviruses (reviewed by Fitzgerald & Semler, 2009). It is possible that these structural differences render EMCV RNA resistant to interaction with AUF1.

The discordance between relocalization of AUF1 during infection and cleavage state raises the question of 3C/3CD proteinase substrate recruitment. Is the difference in the cleavage state of AUF1 during enterovirus and EMCV infection a result of substrate specificity or of intracellular localization? It would be informative to determine whether
AUF1 is cleaved in vitro by recombinant EMCV 3C protease. Perhaps it is the binding of AUF1 to enterovirus RNA that makes it a target for 3C/3CD protease cleavage, and this cleavage acts solely to disrupt the AUF1–viral RNA interaction.

To establish productive infections, viruses must evade cellular antiviral responses, including protecting viral RNA from degradation. As positive-sense RNA viruses, the genomic RNAs of picornaviruses are inherently targets for mRNA decay. As described recently for AUF1 and shown previously for other factors involved in mRNA decay (Xrn1, Dcp1a and PAN3), PV evades, in part, the cellular mRNA decay response by cleavage of essential players in the RNA degradation pathway (Cathcart et al., 2013; Dougherty et al., 2011; Rozovics et al., 2012; Wong et al., 2013). Members of the genus Flavivirus in the family Flaviviridae use a different strategy to avoid host mRNA decay proteins. Their genomic RNAs are capped at the 5′ end but lack a 3′ poly(A) tract. The 3′ NCR of flavivirus RNAs contains a pseudoknot structure that effectively blocks the Xrn1 exoribonuclease, and this stalling has also been linked to the disruption of cellular mRNA degradation (Funk et al., 2010; Moon et al., 2012; Silva et al., 2010). PV has also been shown to contain an RNA element that inhibits RNA decay machinery via its interaction with the IFN-induced RNase L (Townsend et al., 2008). As an alternative to disrupting mRNA decay, viruses may usurp cellular factors to increase viral RNA stability, as has been shown for PV with PCBP2 (Murray et al., 2001). Another AU-rich element-binding protein, HuR, binds to the positive-strand genomic RNA of Sindbis virus (an alphavirus), protecting the viral RNA from deadenylation (Garneau et al., 2008; Sokoloski et al., 2010). Hepatitis C virus, a flavivirus, stabilizes its RNA via binding of the microRNA mir-122 to the 5′ NCR, potentially protecting the 5′ end from exonuclease digestion (Shimakami et al., 2012). EMCV may avoid RNA degradation via an unknown alternative mechanism, perhaps through cleavage of other cellular mRNA decay proteins that are upstream of AUF1 in the mRNA decay pathway, or by usurping stabilizing factors.

In summary, our results highlight the different susceptibilities of RNA viruses to negative regulators produced in infected cells. Such susceptibilities may vary significantly for members of different genera within the family Picornaviridae, as our data have suggested. In addition, the factors determining the sensitivity of picornaviruses to AUF1 may include RNA structure, RNA sequence, subcellular localization, ribonucleoprotein complex composition or other features that, for now, remain to be determined.

Acknowledgements

We thank Sonia Maciejewski for critical comments on the manuscript. We are indebted to Robert Schneider for generously providing the MEF-AUF1+/+ and MEF-AUF1−/− cell lines, Yuri Bochkov for the HRV1a virus stock and Ann C. Palmenberg for the plasmid encoding EMCV cDNA. We thank Hung Nguyen and MyPhuong Tran for their expert technical assistance. We also thank Adeyla Syed at the UCI Optical Biology Core for confocal microscopy training. Confocal microscopy images were generated at the UCI Optical Biology Core facility, which is supported by the National Institutes of Health (Public Health Service grant AI026765) and by the California Center for Antiviral Drug Discovery (a Multicampus Research Program Initiative from the University of California).

References


